Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma
Retrieved on:
Wednesday, February 24, 2021
Oncology, Health, Clinical trials, Research, Pharmaceutical, Science, Medical specialties, Cancer, Clinical medicine, CALYM, Cancer research, Lymphoma, Antibody-drug conjugates, Gilles Salles, Kite Pharma, the Collaboration, EZH1 and EZH2, Valemetostat, B-Cell Lymphoma, LYSA-LYSARC-CALYM, A Multidisciplinary Research Ecosystem, Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and LYSA-LYSARC-CALYM today announced that they have entered a strategic research collaboration to study valemetostat (DS-3201), Daiichi Sankyos potential first-in-class EZH1/2 dual inhibitor, in B-cell malignancies starting with a phase 2 study in patients with five subtypes of relapsed/refractory B-cell lymphoma.
Key Points:
- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and LYSA-LYSARC-CALYM today announced that they have entered a strategic research collaboration to study valemetostat (DS-3201), Daiichi Sankyos potential first-in-class EZH1/2 dual inhibitor, in B-cell malignancies starting with a phase 2 study in patients with five subtypes of relapsed/refractory B-cell lymphoma.
- We are pleased to join forces with Europes largest lymphoma research organization to advance and strengthen the development of valemetostat as a potential novel precision medicine for patients with relapsed/refractory B-cell lymphoma, said Arnaud Lesegretain, Vice President, Global Oncology Development, Alpha Portfolio, Daiichi Sankyo.
- Under the agreement, LYSA-LYSARC will execute a multi-center, non-randomized, open-label phase 2 study to evaluate the safety and efficacy of valemetostat in six cohorts of patients with relapsed/refractory B-cell lymphoma.
- The Lymphoma Academic Research Organization, or LYSARC, is the LYSA operational structure that conducts clinical research projects on lymphomas at the international level.